0001607678 2026-09-24 2026-09-24 0001607678 1 2026-09-24 2026-09-24 0001607678 2 2026-09-24 2026-09-24 iso4217:USD pure S-3 424B5 EX-FILING FEES 333-297820 0001607678 Viking Therapeutics, Inc. N/A N/A S-3 Viking Therapeutics, Inc. false Debt Convertible into Equity 2.00% Convertible Senior Notes due 2032 true 258750000.00 0.0001381 35733.38 false Equity Common Stock, par value $0.00001 per share true 0.0001381 0.00 258750000.00 35733.38 0.00 0.00 35733.38 The amount registered is $258,750,000.00, which represents the aggregate principal amount of 2.00% Convertible Senior Notes due 2032 (the "Notes") whose offer and sale are registered by the registration statement relating to the prospectus supplement to which this exhibit is attached. This amount includes $33,750,000 aggregate principal amount of Notes that may be offered and sold pursuant to the exercise in full of the underwriters' over-allotment option to purchase additional Notes (the "Additional Notes"). The amount set forth in the column titled "Maximum Aggregate Offering Price" includes the maximum aggregate offering price attributable to the Additional Notes. The registration fee is calculated in accordance with Rule 457(r) of the Securities Act of 1933, as amended. This "Calculation of Filing Fee" table filed as Exhibit 107 to the Registrant's Registration Statement on Form S-3ASR (File No. 333-297820) in accordance with Rule 456(b) and 457(r) under the Securities Act of 1933, as amended. The amount registered includes an indeterminate number of shares of common stock, $0.00001 par value per share (the "Common Stock"), of Viking Therapeutics, Inc., issuable upon conversion of the Notes. The initial maximum conversion rate of the Notes is 28.5714 shares of Common Stock per $1,000 principal amount of Notes. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the amount of shares of Common Stock whose offer and sale is registered by the registration statement relating to the prospectus supplement to which this exhibit is attached includes an indeterminate number of shares of Common Stock that may be issued in connection with stock splits, stock dividends, or similar transactions. No additional consideration will be received in connection with the exercise of the conversion privilege of the Notes. Pursuant to Rule 457(i) under the Securities Act, no separate registration fee is required for the shares of Common Stock issuable upon conversion of the Notes because no additional consideration is to be received in connection with the exercise of the conversion privilege of the Notes. 258750000.00 true